Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

What's in the Cards for Geron (GERN) This Earnings Season?

2018-02-20 zacks
Geron Corporation (GERN - Free Report) is expected to report fourth-quarter 2017 results on Mar 7. (80-1)

Imetelstat Might Be Brought Down By Hy's Law

2018-02-20 seekingalpha
We believe imetelstat may have a patient that meets Hy’s Law, a concept that the FDA uses to judge liver toxicity. (41-0)

The No BS Plan: Week 1 Report

2018-02-20 seekingalpha
This is the first of a continuing series of reports on the actions take by the virtual portfolio, the "No BS plan" (170-1)

It May Never Be Celgene, But It's A Mistake To Discount Geron

2018-02-14 seekingalpha
A more moderate stance on the company bears out favorable chances for their lead drug, with significant risk. (96-1)

GERN / Geron Corp. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 GERON CORP COMMON STOCK Cusip #374163103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #374163103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 19,739,475 Item 8: 0 Item 9: 19,739,475 Item 11: 12.396% Item 12: HC Cusip #374163103 Item 1: Reporting Person - Abigail P.

GERN / Geron Corp. / FMR LLC / Fidelity - 3G/A (Passive Investment)

2018-02-13 sec.gov
SCHEDULE 13G Amendment No. 4 GERON CORP COMMON STOCK Cusip #374163103 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #374163103 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 0 Item 6: 0 Item 7: 19,739,475 Item 8: 0 Item 9: 19,739,475 Item 11: 12.396% Item 12: HC Cusip #374163103 Item 1: Reporting Person - Abigail P.

Geron: Imetelstat's History Of Deaths And Safety Issues

2018-02-09 seekingalpha
It appears that the FDA may be investigating continued safety issues with imetelstat in its current clinical trials that may result in another clinical hold. (41-0)

5 High Risk/High Reward Ways to Play the Rebound | InvestorPlace

2018-02-07 investorplace
Stocks are finding their footing on Wednesday, with the Dow Jones Industrial Average holding with a gain of more than 100 points as of this writing. Meanwhile, the CBOE Volatility Index is falling back to earth and investors are leaving their panic attack. (80-0)

GERN / Geron Corp. CURRENT REPORT (Current Report)

2018-02-02 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 30, 2018 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-20859 75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.

Little Geron May Soon Be Nipping At The Heels Of Celgene And Incyte

2018-01-29 seekingalpha
Geron may be the real nightmare Celgene's investors fear and may soon become reality as Imetelstat shows superior results compared to Revlimid in Myelodysplastic Syndrome patients. (112-6)

GERN / Geron Corp. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-25 sec.gov
us3741631036_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) GERON CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 374163103 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------------

GERN / Geron Corp. / BlackRock Inc. - 3G/A (Passive Investment)

2018-01-25 sec.gov
us3741631036_012418.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) GERON CORPORATION -------------------------------------------------------- (Name of Issuer) Common Stock -------------------------------------------------------- (Title of Class of Securities) 374163103 -------------------------------------------------------- (CUSIP Number) December 31, 2017 ----------------------------------------------------

The Toxicity Of Geron's Imetelstat May Lead To Accelerated FDA Approval

2018-01-12 seekingalpha
Median survival for patients taking Imetelstat may already exceed double and may soon exceed triple the expected timeline for patients admitted into the iMbark trial. (53-9)

GERN / Geron Corp. CURRENT REPORT (Current Report)

2018-01-08 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ___________ FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of Earliest Event Reported): January 8, 2018 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware      0-20859     75-2287752 (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.

3 Biotechs For The January Effect

2018-01-03 seekingalpha
In my view, three biotech microcaps may yield among the best risk/reward scenarios for investors today. (182-5)


GERN : Geron Corporation Stock Analysis and Research Report

Geron Corporation is a biopharmaceutical company that currently supports the clinical stage development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies, by Janssen Biotech, Inc., or Janssen. Early clinical data, including molecular responses in essential thrombocythemia, or ET, and remission responses, including reversal of bone marrow fibrosis, in myelofibrosis, or MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

In November 2014, Geron entered into a collaboration and license agreement, or the Collaboration Agreement, pursuant to which the company granted Janssen the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses. The Collaboration Agreement became effective in December 2014 and the company received $35 million from Janssen ...

Click for full article
CUSIP: 374163103